Humana Inc. (NYSE:HUM) Shares Purchased by South Dakota Investment Council

South Dakota Investment Council grew its stake in shares of Humana Inc. (NYSE:HUM) by 39.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 153,317 shares of the insurance provider’s stock after acquiring an additional 43,719 shares during the quarter. Humana comprises approximately 0.8% of South Dakota Investment Council’s investment portfolio, making the stock its 13th largest holding. South Dakota Investment Council’s holdings in Humana were worth $38,898,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of HUM. FMR LLC increased its holdings in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Humana by 55.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after buying an additional 214,535 shares during the period. Retirement Systems of Alabama increased its holdings in Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock worth $55,563,000 after buying an additional 192,801 shares during the period. Pzena Investment Management LLC increased its holdings in Humana by 8.1% in the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after buying an additional 187,903 shares during the period. Finally, Worldquant Millennium Advisors LLC acquired a new position in Humana in the 3rd quarter worth approximately $50,102,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.32% of the company’s stock.

Humana Trading Down 5.7 %

Shares of HUM stock opened at $255.77 on Friday. The stock’s fifty day moving average is $269.41 and its two-hundred day moving average is $290.00. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a market capitalization of $30.80 billion, a P/E ratio of 25.71, a PEG ratio of 2.05 and a beta of 0.56. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana (NYSE:HUM) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.38%. Humana’s dividend payout ratio is presently 35.58%.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research reports. Cantor Fitzgerald reiterated a “neutral” rating and issued a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Truist Financial increased their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Barclays increased their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Nineteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.